Exhibit 99.1
INVESTORpresentation April 2021 Ofer Haviv, President & CEO
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. 2
Agenda IntroductionFields of activityMain subsidiariesSummary 3 Annex I - Addressing the discovery and development challenges of life science-based productAnnex II - Financial Fundamentals
Our Vision 4 DECODING BIOLOGY Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.
Ag-chemicalsIndustry Life-science product discovery & development challenges Low probability of success with high cost and long time-to-market 5 Pharmaceutical Industry Discovery anddevelopment costsof a new cropprotection product Time to developa new cropprotection product 1995 2000 2005-8 2010-15 Number of years between the firstsynthesis and first sale of product 8.3 9.1 9.8 11.3 CDER’S* annual noveldrug approvals:2010-2019 Worldwide totalpharmaceutical R&Dspend in 2010-2024 Source: Phillips McDougall, 2016 Source: Phillips McDougall, 2016 Source: U.S. Food and Drug Administration Source: Evaluate Pharma May 2019 *Center for Drug Evaluation and Research
The opportunity Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & development. 6 HUMAN HEALTH Agriculture Other Industries
When biology meetsdisruptive technologies;introducing– platform 7 BIG DATA BIOLOGY AI Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-science based products. – Computational Predictive Biology Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results
Tailor-made Engines for product discovery & development The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:MicrobesSmall molecules Genetic elements 8 MICROBES GENETIC ELEMENTS SMALL MOLECULES
Tailor-made Engines for product development 9 DiscoveryComputational selection of the most promising candidates to initiate the product development process. DevelopmentComputational driven solution addressingoptimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to successful commercialization. BIOLOGY BIG DATA AI MICROBES GENETIC ELEMENTS SMALL MOLECULES
10 Business Model 1 Product development through collaborationsJoint development with leading companies for defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will likely be done by the partner. Potential revenue for EvogeneLicensing and research paymentsMilestone paymentsRevenue sharing GMO seed traits for yield and abiotic stress for wheat GMO seed traits for yield and abiotic stress for cornGMO seed traits for ASR resistance for soybean GMO seed traits for nematode resistance Main Business Model Until 2014: GMO seed traits for yield and abiotic stress for corn and soybeanGMO (2013) and genome editing (2019) seed traits for fusarium resistance
Product development through subsidiariesEstablish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations. Potential revenue for EvogeneLicensing and research paymentsConsolidated revenuesDividends (subject to profits generated by subsidiary) 11 Business Model 2 Microbiome based therapeutics Medical cannabis Ag-solutions for castor Ag-chemicals Ag-biologicals Main Business Model from 2015:
Agenda IntroductionFields of activityMain subsidiariesSummary 12 Annex I - Addressing the discovery and development challenges of life science-based productAnnex II - Financial Fundamentals
OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS 13 Potential fields of activity
14 Current life-science based products under development OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH Ag-Biologicals MicrobiomebasedTherapeutics MICROBES Ag-Chemicals Drugs based on small molecules SMALL MOLECULES Ag-solutionsfor castoroil production Seed Traits MedicalCannabis GENETIC ELEMENTS
Development & commercialization through subsidiaries and collaborations 15 OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS Seed Traits [division] * * non-exclusive license
OTHER INDUSTRIES AGRICULTURE HUMAN HEALTH MICROBES SMALL MOLECULES GENETIC ELEMENTS 16 Evogene Group – More to Come We are now evaluating the initiation of discovery and development of new life-science based products in various new fields of activity. Drug optimization* Microbe for aquaculture* High quality food by genome editing* * under evaluation New activity
Evogene Group 17 *Evogene holdings Other Industries 100%* Castor Oil ProductionCastor seeds &growth protocol HumanHealth Microbiome basedTherapeuticsImmuno-oncologyGI- gastrointestinal- related disordersMDRO – multi-drug resistant organisms Medical CannabisHigh yield & consumer traitsTherapeutic traits – currently inflammation & pain 90%* 100%* Seed TraitsYield improvement and drought tolerancePlant diseaseInsect control Agriculture Ag ChemicalsHerbicidesInsecticidesFungicides Ag BiologicalsBio-StimulantsBio-Pesticides 98%* 72%* Internal division of Evogene
Agenda IntroductionFields of activityMain subsidiariesSummary 18 Annex I - Addressing the discovery and development challenges of life science-based productAnnex II - Financial Fundamentals
19 Immuno-oncology program:Combination therapy for cancer with checkpoint inhibitorsPre-clinical stageAddressable market size expected by 2026* – $243BGI related disorders:Inflammatory Bowel Disorder (IBD) – pre-clinical stageIrritable Bowel Syndrome (IBS) – discovery stageAddressable market size expected by 2026: Inflammatory Bowel Disorder $22.4B, Irritable Bowel Syndrome** $3.3BMDRO:Multi Drug Resistant Organisms (antimicrobial resistance)Clostridium Difficile Infection (CDI) – discovery stageMethicillin-resistant Staphylococcus aureus (MRSA)– discovery stageAddressable market size expected by 2026: CDI*** $1.7B, MRSA**** $3.9B Mission:Discovery and development of novel therapies for microbiome-related human disorders using computational biology. 2021IBD - extend pre-clinical studyImmuno-oncology - initiate proof of concept, first in human study2022IBD - initiate first GMP production of drug candidates for IBDImmuno-oncology - readout from proof of concept, first in human study Product Pipeline: | Human Microbiome *https://www.globenewswire.com/news-release/2019/07/17/1884118/0/en/Cancer-Immunotherapy-Market-To-Reach-USD-242-86-Billion-By-2026-Reports-And-Data.html**https://www.bloomberg.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-cagr-10-1-grand-view-research-inc***www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/****www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html Expected main near-term value drivers:
20 Example Results: Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo | Human Microbiome
21 MetaYield Products:Stable enhancement of total plant compounds:Increased compounds per plantIncreased compounds per areaTotal Cannabis market size expected by 2024 – $42.7B* Precise Products:Stable enhancement of specific active compounds for pain and inflammation: Medical indication focusCompound profile focusMedical Cannabis market size expected by 2024 – $25.6B* Mission:Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology. 2021MetaYield - reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022Precise - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation2022MetaYield - commercial launch and initial sales of first product in IsraelPrecise - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023 Product Pipeline: | Medical Cannabis *Source: Arcview Market research/BDS Analytics 2020 Expected main near-term value drivers:
22 Example Results: Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes MetaYield products under development – increased compounds per area, addressing the T20/C4 (THC 16%-24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market | Medical Cannabis
23 Herbicides:Novel MoA (Mode-of-Action) selective/non-selective herbicidesRelevant target crops – Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBDAddressable market size expected by 2022*: $34BLead stage Insecticides:Novel SoA (Site-of-Action)Addressable market size expected by 2022*: $19BHit-to-Lead stage Mission:Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry. 2021New MoA Herbicide - reach a herbicide tolerance trait POC for a ‘Lead’ herbicide under developmentNew MoA Herbicide/SoA Insecticide - sign a licensing agreement for a leading candidate2022New MoA Herbicide - sign a strategic agreement for the development of an ‘Optimized Lead’ compoundNew MoA Herbicide - reach an ‘Optimized Lead’ phase in the herbicide program Product Pipeline: | Ag-Chemicals *https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html Expected main near-term value drivers:
24 Example Results: Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 Leading novel MoA herbicide candidate – displaying efficacy in eradicating multiple important weed species in field tests | Ag-Chemicals (weed)
25 | Ag-Biologicals Bio-stimulants (live microbials for yield improvement):Spring wheat – seed treatment/soil application – development stage 2Corn – seed treatment – pre-development stageAddressable market size*: corn – 120M acres, spring wheat – 25M acresBio-pesticides (live microbials for pest protection):Mildew, fruit rot for fruit and vegetables (initial focus on grapes) – foliar application – development stage 1Seedling disease for corn, soy – seed treatment for disease protection – pre-development stageBio-insecticides – initial focus corn (seed treatment), soy (foliar) – pre-development stageAddressable market size*: mildew, fruit rot – $550M, seedling diseases – $500M, bio-insecticides – $1.5B. Mission:Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology. 2021Fruit rot bio-fungicide – product advancement of LAV311 or 312 development towards regulationBio-stimulant - conduct pre-commercial trials for LAV211 in spring wheat 2022Bio-stimulant - initial product sales of LAV211 for spring wheatFruit rot bio-fungicide - file for regulatory approval for leading product candidate LAV311 or LAV312 Product Pipeline: *Company estimation Expected main near-term value drivers:
26 | Ag-Biologicals Example of treatment with LAV312 against Botrytis Cinerea in vines – untreated control vs treated vines Lavie Bio’s wheat field in the USA during harvest
Subsidiaries - expected main near-term value drivers 2021 2022 Inflammatory Bowel Disease (IBD) - extend pre-clinical study Immuno-oncology - initiate proof of concept, first in human study IBD - initiate first GMP production of drug candidates for IBD Immuno-oncology - readout from proof of concept, first in human study MetaYield - reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022 Precise - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation MetaYield - commercial launch and initial sales of first product in Israel Precise - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023 New MoA Herbicide - reach a herbicide tolerance trait POC for a ‘Lead’ herbicide under development New MoA Herbicide/SoA Insecticide - sign a licensing agreement for a leading candidate New MoA Herbicide - sign a strategic agreement for the development of an ‘Optimized Lead’ compound New MoA Herbicide - reach an ‘Optimized Lead’ phase in the herbicide program Fruit rot bio -fungicide – product advancement of LAV311 or 312 development towards regulation Bio-stimulant - conduct pre-commercial trials for LAV211 in spring wheat Bio-stimulant - initial product sales of LAV211 for spring wheat Bunch rot bio-fungicide - file for regulatory approval for leading product candidate LAV311 or LAV312 27 Collaboration Regulation Pipeline Product Launch
Agenda IntroductionFields of activityMain subsidiariesSummary 28 Annex I - Addressing the discovery and development challenges of life science-based productAnnex II - Financial Fundamentals
29 Summary Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies The CPB’s three unique engines target to improve the development of products based on the following core components:MicroBoost AI – for products based on microbesChemPass AI – for products based on small moleculesGeneRator AI – for products based on genetic elements Four main market-oriented subsidiaries, each with a clear milestone roadmap: Biomica – human-microbiome based therapeuticsCanonic – medical cannabisAgPlenus – ag-chemicalsLavie Bio – ag-biologicals Dual based business model - utilizing Evogene’s solutions for:Product development & commercialization through collaborationsProduct development & commercialization through subsidiaries Significant catalysts expected in the next 12 months towards 2022 product commercialization & strategic collaborations
THANK You!
Annex I:Addressing the discovery and development challenges of life science-based product 31
32 Efficacy Safety Selectivity Shelf-life Other ProductLaunch Candidate Selection ProductDefinition Discovery Development The challenge in creatinglife-science based products
33 Candidate Selection ProductDefinition Common practiceDiscovery – selection of product candidates mainly addressing efficacy The challenge in creatinglife-science based products Efficacy Safety Selectivity Shelf-life Other ProductLaunch
34 Candidate Selection ProductDefinition Low probability of successLong time to marketHigh development costs Development – inefficient optimization & difficulty in addressing a single challenge without impairing others The challenge in creatinglife-science based products Efficacy Safety Selectivity Shelf-life Other ProductLaunch Common practiceDiscovery – selection of product candidates mainly addressing efficacy
Evogene’s AI-based solution:Discovery 35 Candidate Selection ProductDefinition A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Efficacy Safety Selectivity Shelf-life Other ProductLaunch
Evogene’s AI-based solution:Development 36 Candidate Selection ProductDefinition A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Efficacy Safety Selectivity Shelf-life Other ProductLaunch
37 Evogene’s AI engines provide tailor-made solutions Development Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes. DiscoveryComputational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes.
Annex II:Financial Fundamentals 38
Key Financials:Balance Sheet Key Points:Consolidated cash position: ~$48.2 million as of 31.12.2020, ~$13 million appropriated to Lavie BioNo bank debtEstimated net cash usage for 2021, excluding Lavie Bio: $20-$22 millionListed on TASE (2007) and NASDAQ (2016) 39 Thousands of US $ 31.12.2020 31.12.2019 Current Assets 51,823 49,027 Long-Term Assets 20,092 22,337 Total Assets 71,915 71,364 Current Liabilities 9,676 5,746 Long-Term Liabilities 5,357 5,401 Equity attributable to equity holders of the Company 46,045 50,144 Non-controlling interest 10,837 10,073 Total Liabilities & Shareholders Equity 71,915 71,364 39